UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...
The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...
Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a ...
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, ...
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Scynexis with a $214 million contract for ...
Precision Neurosciences, which specializes in brain-computer interface technology, raised $250 million in an oversubscribed ...
Kodiak plans to file for FDA approval of tarcocimab, an anti-VEGF drug also called Zenkuda, in the fourth quarter. The ...
Pharmaceutical research is in the early stages of a transition that promises to advance drug development as profoundly as the ...
As the race to harness CAR-T cells for autoimmune diseases hits a rough patch, a Bay Area biotech is gliding over the ...
Merck paid Daiichi $4 billion upfront in 2023 to partner on three ADCs. The FDA rejected a request for approval of one of the ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results